

REMARKS

The above Preliminary Amendment amends the specification to conform to and properly reference the sequences in the Sequence Listing. Applicants' representative further states that the Sequence Listing adds no new matter to the application.

In view of the discovery by the Applicants of a typographical error in SEQ ID NO:3 as originally submitted in Figure 13, and subsequent amendment of SEQ ID NO:3 to correct this matter in the present Preliminary Amendment, Applicants submit herewith an original Sequence Listing which lists the corrected sequence of SEQ ID NO:3. The typographical error has been corrected by the insertion of a "t" residue at position 24805. Thus, enclosed herewith in full compliance with 37 C.F.R. 1.821-1.825 is a Sequence Listing to be inserted into the specification. The Sequence Listing in no way introduces new matter into the specification.

Also submitted herewith in full compliance with 37 C.F.R. 1.821-1.825 is a computer readable disk copy of the Sequence Listing. The disk copy of the Sequence Listing is identical to the paper copy, except that it lacks formatting.


Prompt and favorable consideration on the merits are respectfully requested.

Attached hereto is a mark-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**VERSION WITH MARKINGS TO SHOW CHANGES MADE.**"

To the extent necessary, a petition for an extension of time under 37 C.F.R. 1.136 is hereby made. Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 500417 and please credit any excess fees to such deposit account.

Respectfully submitted,

MCDERMOTT, WILL & EMERY


Joseph Hyosuk Kim, PhD
Registration No. 41,425

600 13th Street, N.W.
Washington, DC 20005-3096
(202) 756-8000 JHK:ajb
Date: May 16, 2001
Facsimile: (202) 756-8087

Enclosures: Sequence Listing and CRF; and Request for Approval of Drawing Corrections

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Page 3, the paragraph beginning at line 19 has been amended as follows:

--According to a first aspect, the present invention consists in an isolated DNA molecule comprising a nucleic acid sequence encoding the genome of ovine adenovirus (OAV287) substantially as shown in Figure 1 (SEQ ID NO:1) or a functionally equivalent nucleic acid sequence. Preferably, the nucleic acid sequence encoding the genome of the adenovirus is substantially as shown in Figure 1.--

Page 6, the fourth full paragraph beginning at line 26 has been amended as follows:

--Figure 1 is the nucleic acid sequence of the OAV287 genome beginning at base 1 of the left-hand ITR (SEQ ID NO:1).--

Page 8, the first full paragraph beginning at line 5 has been amended as follows:

--Figure 9 is a map of a plasmid pMT used for the assembly of gene expression cassettes. Fragments containing the OAV287 major late promoter and tripartite leader sequences are linked and precede a multiple cloning site (SEQ ID NO:2) for the insertion of genes of interest. A tandem polyadenylation signal (AATAA) follows.--

Page 8, the paragraph beginning after line 27 as amended in the Preliminary Amendment of December 16, 1999, has been amended as follows:

--Figure 13 is a modified nucleic acid sequence of the OAV287 genome beginning at base 1 of the left hand ITR (SEQ ID NO:3).--